BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stevens VW, Khader K, Echevarria K, Nelson RE, Zhang Y, Jones M, Timbrook TT, Samore MH, Rubin MA. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci. Clinical Infectious Diseases 2020;71:645-51. [DOI: 10.1093/cid/ciz871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Poudel A, Pokhrel A, Oludiran A, Coronado EJ, Alleyne K, Gilfus MM, Gurung RK, Adhikari SB, Purcell EB. Unique Features of Alarmone Metabolism in Clostridioides difficile. J Bacteriol 2022;:e0057521. [PMID: 35254095 DOI: 10.1128/jb.00575-21] [Reference Citation Analysis]
2 Gnocchi M, Gagliardi M, Gismondi P, Gaiani F, De' Angelis GL, Esposito S. Updated Management Guidelines for Clostridioides difficile in Paediatrics. Pathogens 2020;9:E291. [PMID: 32316346 DOI: 10.3390/pathogens9040291] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tanwar SSS, Weiner-Lastinger LM, Bell JM, Allen-Bridson K, Bagchi S, Dudeck MA, Edwards JR. Laboratory-identified vancomycin-resistant enterococci bacteremia incidence: A standardized infection ratio prediction model. Infect Control Hosp Epidemiol 2021;:1-5. [PMID: 34085620 DOI: 10.1017/ice.2021.215] [Reference Citation Analysis]
4 Nix CD, Messer WB, Hale ML, Lewis JS 2nd, Strasfeld LM. Impact of a Clostridioides Difficile Testing Computerized Clinical Decision Support Tool on an Adult Stem Cell Transplantation and Hematologic Malignancies Unit. Transplant Cell Ther 2021;27:94.e1-5. [PMID: 33045386 DOI: 10.1016/j.bbmt.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yin J, Kociolek LK, Same RG, Hsu AJ, Amoah J, Tamma PD. Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections. Open Forum Infect Dis 2019;6:ofz492. [PMID: 31950069 DOI: 10.1093/ofid/ofz492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Dureja C, Olaitan AO, Hurdle JG. Mechanisms and impact of antimicrobial resistance in Clostridioides difficile. Current Opinion in Microbiology 2022;66:63-72. [DOI: 10.1016/j.mib.2022.01.004] [Reference Citation Analysis]
7 Lenggenhager L, Zanella MC, Poncet A, Kaiser L, Schrenzel J. Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland. BMJ Open 2020;10:e036342. [PMID: 32928850 DOI: 10.1136/bmjopen-2019-036342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Correa-Martínez CL, Hagemeier NCJ, Froböse NJ, Kampmeier S. Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci. Pharmaceuticals (Basel) 2021;14:1066. [PMID: 34832848 DOI: 10.3390/ph14111066] [Reference Citation Analysis]
9 Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020;52:12-20. [PMID: 31801387 DOI: 10.1080/07853890.2019.1701703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]